YTB323, Flebogamma DIF 50 mg/ml solution for infusion, TOCILIZUMAB, FLUDARABINE PHOSPHATE, CYCLOPHOSPHAMIDE
CYTB323O12101
Phase 2 small_molecule active
Quick answer
YTB323, Flebogamma DIF 50 mg/ml solution for infusion, TOCILIZUMAB, FLUDARABINE PHOSPHATE, CYCLOPHOSPHAMIDE for Treatment-resistant generalized Myasthenia Gravis is a Phase 2 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Treatment-resistant generalized Myasthenia Gravis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active